TrialCancer science2026

Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer.

Katsutoshi Oda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.